📣 VC round data is live. Check it out!

TELA Bio Valuation Multiples

Discover revenue and EBITDA valuation multiples for TELA Bio and similar public comparables like Luna Innovations, RenovoRx, Myomo, Mauna Kea Technologies and more.

TELA Bio Overview

About TELA Bio

TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. Its growing product portfolio is purposefully designed to leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.


Founded

2012

HQ

United States

Employees

209

Financials (LTM)

Revenue: $83M
EBITDA: ($30M)

EV

$57M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

TELA Bio Financials

TELA Bio reported last 12-month revenue of $83M and negative EBITDA of ($30M).

In the same LTM period, TELA Bio generated $56M in gross profit, ($30M) in EBITDA losses, and had net loss of ($39M).

Revenue (LTM)


TELA Bio P&L

In the most recent fiscal year, TELA Bio reported revenue of $80M and EBITDA of ($31M).

TELA Bio is unprofitable as of last fiscal year, with gross margin of 68%, EBITDA margin of (38%), and net margin of (48%).

See analyst estimates for TELA Bio
LTMLast FY202320242025202620272028
Revenue$83M$80M$58M$69M$80M
Gross Profit$56M$54M$40M$46M$54M
Gross Margin68%68%69%67%68%
EBITDA($30M)($31M)($41M)($32M)($32M)
EBITDA Margin(36%)(38%)(70%)(46%)(40%)
EBIT Margin(40%)(42%)(75%)(60%)(42%)
Net Profit($39M)($39M)($47M)($38M)($39M)
Net Margin(47%)(48%)(80%)(55%)(48%)
Net Debt$5M

Financial data powered by Morningstar, Inc.

TELA Bio Stock Performance

TELA Bio has current market cap of $40M, and enterprise value of $57M.

Market Cap Evolution


TELA Bio's stock price is $0.89.

TELA Bio share price increased by 1.9% in the last 30 days, and decreased by 35.8% in the last year.

TELA Bio has an EPS (earnings per share) of $-0.87.

See more trading valuation data for TELA Bio
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$57M$40M0.0%1.9%2.8%-35.8%$-0.87

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

TELA Bio Valuation Multiples

TELA Bio trades at 0.7x EV/Revenue multiple, and (1.9x) EV/EBITDA.

See NTM and 2027E valuation multiples for TELA Bio

EV / Revenue (LTM)


TELA Bio Financial Valuation Multiples

As of May 26, 2026, TELA Bio has market cap of $40M and EV of $57M.

TELA Bio has a P/E ratio of (1.0x).

LTMLast FY202320242025202620272028
EV/Revenue0.7x0.7x1.0x0.8x0.7x
EV/EBITDA(1.9x)(1.8x)(1.4x)(1.8x)(1.8x)
EV/EBIT(1.7x)(1.7x)(1.3x)(1.4x)(1.7x)
EV/Gross Profit1.0x1.0x1.4x1.2x1.0x
P/E(1.0x)(1.0x)(0.9x)(1.1x)(1.0x)
EV/FCF(1.7x)(2.0x)(1.4x)(1.3x)(2.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified TELA Bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

TELA Bio Margins & Growth Rates

TELA Bio grew revenue by 8% but EBITDA decreased by 7% in the last fiscal year.

In the most recent fiscal year, TELA Bio reported gross margin of 68%, EBITDA margin of (38%), and net margin of (48%).

See estimated margins and future growth rates for TELA Bio

TELA Bio Margins

Last FY202420252026202720282029
Gross Margin68%67%68%68%
EBITDA Margin(38%)(46%)(40%)(33%)
EBIT Margin(42%)(60%)(42%)(38%)
Net Margin(48%)(55%)(48%)(45%)
FCF Margin(36%)(61%)(36%)(43%)

TELA Bio Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth8%19%16%8%
Gross Profit Growth8%16%17%8%
EBITDA Growth(7%)(22%)2%(11%)
EBIT Growth(3%)(5%)(19%)(3%)
Net Profit Growth1%(19%)3%1%
FCF Growth31%3%(33%)31%

Data powered by FactSet, Inc. and Morningstar, Inc.

TELA Bio Operational KPIs

TELA Bio's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.

TELA Bio's Rule of 40 is (25%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

TELA Bio's Rule of X is (13%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for TELA Bio
LTMLast FY202320242025202620272028
Rule of 40(27%)(25%)
Bessemer Rule of X(14%)(13%)
Revenue per Employee$0.4M
Opex per Employee$0.4M
S&M Expenses to Revenue78%79%102%93%79%
G&A Expenses to Revenue19%20%25%21%20%
R&D Expenses to Revenue11%11%16%13%11%
Opex to Revenue110%144%127%110%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

TELA Bio Competitors

TELA Bio competitors include Luna Innovations, RenovoRx, Myomo, Mauna Kea Technologies, Abingdon Health, Biohit, Ortoma, Theraclion, Diagnostic Medical Systems and Optomed.

Most TELA Bio public comparables operate across Medical Devices, HealthTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Luna Innovations
RenovoRx24.6x14.1x(2.2x)
Myomo1.1x1.0x(3.8x)(4.1x)
Mauna Kea Technologies5.1x5.2x3.3x(13.5x)
Abingdon Health3.1x2.2x(10.3x)(22.8x)
Biohit2.0x9.6x
Ortoma5.1x4.9x(78.0x)(26.7x)
Theraclion43.9x(6.2x)

This data is available for Pro users. Sign up to see all TELA Bio competitors and their valuation data.

Start Free Trial

TELA Bio Funding History

Before going public, TELA Bio raised $87M in total equity funding, across 7 rounds.


TELA Bio Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Nov-18Seed$2M
Mar-18SeedProMedica Health System$1M
Oct-17Undisclosed stageOrbiMed; Pacira BioSciences; Quaker Partners; Signet Healthcare Partners$25MTELA Bio is a privately-held surgical reconstruction company marketing the proprietary OviTex™ portfolio of products for ventral hernia repair and abdominal wall reconstruction. The OviTex line features a unique embroidered construction combining biologic and synthetic materials in permanent and resorbable formulations to enable fluid and cell movement, addressing various hernia repair and abdominal wall needs. In October 2017, Pacira Pharmaceuticals committed to invest up to $25 million in TELA Bio, with an initial $15 million investment and up to an additional $10 million upon fulfillment of certain performance milestones or scenarios. Pacira received one seat on the TELA Bio Board of Directors, and the agreement included a 12-month standstill provision precluding a change of control. The funding was intended to scale up TELA Bio's clinical and commercial efforts for existing hernia repair and abdominal wall reconstruction products, as well as to develop new OviTex products for additional soft tissue procedures such as breast reconstruction. Pacira Pharmaceuticals, a specialty pharmaceutical company focused on acute care products like EXPAREL, acted as the lead investor, leveraging its commercial experience in the surgical community. Antony Koblish, TELA Bio's president and CEO (formerly of Orthovita), highlighted the investment's role in enhancing innovation in surgical reconstruction. No financial metrics such as post-money valuation, revenue, ARR, EBITDA, or valuation multiples were disclosed in the announcement or related filings for this round. RBC Capital Markets LLC served as financial advisor to Pacira. TELA Bio remained privately held following the investment.
Jan-17Series A$7MTELA Bio raised $7.4 million in an equity financing round from 16 unnamed investors, as disclosed in an SEC filing around early 2017. The Malvern, Pa.-based company develops OviTex reinforced bioscaffolds for hernia repair and abdominal wall reconstruction, combining biologic and synthetic materials with either permanent or resorbable polymers. TELA Bio received FDA 510(k) clearance for the OviTex portfolio in July prior to the round and launched the product immediately afterward.
Nov-14Pre-seed$500K
Oct-14Undisclosed stage$45MTELA Bio is a Pennsylvania-based regenerative surgical implants company specializing in hernia repair and abdominal wall reconstruction devices. The company produces OviTex reinforced bioscaffolds, which combine polymer and biologic materials in an embroidered construction. In October 2014, TELA Bio raised $45.3 million in equity funding, following previous rounds of $16.1 million in 2012 and $6 million in 2013. The company was led by Antony Koblish, who previously led orthobiologics maker Orthovita before its acquisition by Stryker for $316 million. TELA Bio received FDA 510(k) clearance for its OviTex portfolio in July 2014 and launched the device immediately following clearance. In October 2014, the company settled patent infringement litigation with Acelity subsidiary LifeCell, allowing it to continue manufacturing its OviTex line of reinforced scaffolds for abdominal surgery. The company continued raising capital through subsequent rounds, eventually going public in November 2019 via a $52 million IPO.
Aug-13Series A$6M

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About TELA Bio

When was TELA Bio founded?TELA Bio was founded in 2012.
Where is TELA Bio headquartered?TELA Bio is headquartered in United States.
How many employees does TELA Bio have?As of today, TELA Bio has over 209 employees.
Who is the CEO of TELA Bio?TELA Bio's CEO is Anthony Koblish.
Is TELA Bio publicly listed?Yes, TELA Bio is a public company listed on Nasdaq.
What is the stock symbol of TELA Bio?TELA Bio trades under TELA ticker.
When did TELA Bio go public?TELA Bio went public in 2019.
Who are competitors of TELA Bio?TELA Bio main competitors include Luna Innovations, RenovoRx, Myomo, Mauna Kea Technologies, Abingdon Health, Biohit, Ortoma, Theraclion, Diagnostic Medical Systems, Optomed.
What is the current market cap of TELA Bio?TELA Bio's current market cap is $40M.
What is the current revenue of TELA Bio?TELA Bio's last 12 months revenue is $83M.
What is the current revenue growth of TELA Bio?TELA Bio revenue growth (NTM/LTM) is 9%.
What is the current EV/Revenue multiple of TELA Bio?Current revenue multiple of TELA Bio is 0.7x.
Is TELA Bio profitable?No, TELA Bio is not profitable.
What is the current EBITDA of TELA Bio?TELA Bio has negative EBITDA and is not profitable.
What is TELA Bio's EBITDA margin?TELA Bio's last 12 months EBITDA margin is (36%).
What is the current EV/EBITDA multiple of TELA Bio?Current EBITDA multiple of TELA Bio is (1.9x).
What is the current FCF of TELA Bio?TELA Bio's last 12 months FCF is ($32M).
What is TELA Bio's FCF margin?TELA Bio's last 12 months FCF margin is (39%).
What is the current EV/FCF multiple of TELA Bio?Current FCF multiple of TELA Bio is (1.7x).
How many companies TELA Bio has acquired to date?TELA Bio hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies TELA Bio has invested to date?TELA Bio hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to TELA Bio

Lists including TELA Bio

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial